BEAM Stock Beam Therapeutics Inc.
US · NasdaqGSLast in our picks 2026-10-21 — not in the current list; analysis below is from that screen
Base-editing platform and clinical catalysts offer high-growth optionality despite elevated biotechnology risk.
Future value: $53.73 (+115.52%) · 6-12 months
Signal breakdown
- ▸Consensus Strong Buy; Wells Fargo maintained a $70 target.
- ▾Below 50-day MA (-4.66%)
- ▸~116% upside to price target
Is BEAM a buy right now?
Trend: BEAM is trading below the 50-day average (-8.36%), RSI 50 — neutral momentum, with a 3-month return of -9.51%.
Valuation & quality: Beam Therapeutics Inc. trades on forward P/E -5.0, price-to-book 2.23; fundamentals show net margin -55.4%, return on equity -8.2%, revenue growth -94.2% year on year.
Analyst consensus: 13 analysts have a mean 12-month price target of $52.15 (+119.2% vs the last close; range $26.00 – $80.00), consensus rating “strong buy”.
Our screen: BUY (score 2) — Base-editing platform and clinical catalysts offer high-growth optionality despite elevated biotechnology risk.
Computed from end-of-day data; not personal advice.
Our track record with BEAM
First flagged in our daily picks as BUY on 2026-10-21 at $24.93 — -4.6% since.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -16.30% | +27.30% | +8.60% | +4.20% | -25.60% | +15.30% | -16.90% | -2.70% |
Fundamentals
Analyst price target
Technical signals
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 540 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.